The history of ifosfamide

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Ifosfamide was developed by investigators at AstaWerke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chlorethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less myelosuppression, but more commonly produced hemorrhagic cystitis as its dose-limiting toxicity. This toxicity has been minimized with the urothelial protective agents mesna and N-acetylcysteine. Thus, increasing doses have been administered and a new spectrum of toxicities observed, including neurotoxicity, hematologic toxicity, nephrotoxicity, and acidosis. Ifosfamide has been shown to have a broad spectrum of clinical activity in various cancers. Questions remain as to the optimal doses and schedules.

Original languageEnglish (US)
Pages (from-to)2-6
Number of pages5
JournalSeminars in oncology
Volume19
Issue number6 SUPPL. 12
StatePublished - Dec 1992

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'The history of ifosfamide'. Together they form a unique fingerprint.

  • Cite this